Baxter to market Halozyme's Hylenex in Europe

New York, Dec. 8 - Halozyme Therapeutics, Inc. said Baxter Healthcare Corp. will market its Hylenex product in Europe under an amendment to the two companies' exclusive distribution agreement.

Once regulatory approval is received, Baxter will have exclusive rights to market the product in the European Union members and some other European countries.

Baxter and Halozyme will share the costs of obtaining approval. Baxter will pay sales and marketing costs up to an annual threshold, after which the two companies will split the expense.

Halozyme will receive 50% of the gross profit from sales, according to an 8-K filing with the Securities and Exchange Commission.

Halozyme is a biopharmaceutical company based in San Diego. Hylenex is a synthetic hyaluronidase enzyme used to assist subcutaneous diffusion of anesthesia in ophthalmic surgery.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.